Biodexa Pharmaceuticals PLC Files 6-K, Incorporates Exhibits

Ticker: BDRX · Form: 6-K · Filed: Jun 13, 2024 · CIK: 1643918

Biodexa Pharmaceuticals PLC 6-K Filing Summary
FieldDetail
CompanyBiodexa Pharmaceuticals PLC (BDRX)
Form Type6-K
Filed DateJun 13, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: filing, registration-statement, administrative

Related Tickers: BDRX

TL;DR

Biodexa (BDRX) filed a 6-K, incorporating exhibits into F-3 and F-1 filings. Standard procedure.

AI Summary

Biodexa Pharmaceuticals PLC filed a Form 6-K on June 13, 2024, to incorporate by reference Exhibit 99.1 into its existing Registration Statements on Form F-3 (File No. 333-233901) and Form F-1 (File No. 333-240984). The company, formerly known as Midatech Pharma Plc, is based in Cardiff, United Kingdom.

Why It Matters

This filing is procedural, incorporating previous information into active registration statements, which is crucial for ongoing securities offerings or compliance.

Risk Assessment

Risk Level: low — This is a routine administrative filing that incorporates previously disclosed information into existing registration statements.

Key Players & Entities

FAQ

What is the purpose of this Form 6-K filing?

The purpose is to incorporate by reference Exhibit 99.1 into the Company's Registration Statements on Form F-3 (File No. 333-233901) and Form F-1 (File No. 333-240984).

When was this Form 6-K filed?

This Form 6-K was filed on June 13, 2024.

What is the principal executive office address of Biodexa Pharmaceuticals PLC?

The principal executive office is located at 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom.

What was Biodexa Pharmaceuticals PLC formerly known as?

Biodexa Pharmaceuticals PLC was formerly known as Midatech Pharma Plc, with a date of name change on June 2, 2015.

Does Biodexa Pharmaceuticals PLC file annual reports under Form 20-F or Form 40-F?

Biodexa Pharmaceuticals PLC files annual reports under Form 20-F, as indicated by the checkmark in the filing.

Filing Stats: 204 words · 1 min read · ~1 pages · Grade level 11.5 · Accepted 2024-06-13 09:48:30

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Biodexa Pharmaceuticals PLC (Registrant) Date: June 13, 2024 /s/ Stephen Stamp Stephen Stamp Chief Executive Officer, Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing